CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Metabolix,
Inc. (NASDAQ: MBLX), an innovation-driven bioscience company focused
on delivering sustainable solutions for plastics, chemicals and energy,
today announced the promotion of Max Senechal to vice president,
biobased chemicals and his appointment to the executive management team.
Mr. Senechal will be responsible for the commercialization of
Metabolix's biobased industrial chemicals program, including the
coordination of critical technical milestones and development of the
customer base globally.
"We're pleased to recognize Max for his recent leadership of the
Company's technical and commercial activities related to our biobased
industrial chemicals platform," commented Richard P. Eno, president and
CEO of Metabolix. "With recent advances in our chemicals business and
growing market interest in our technology, Max will lead the team
driving this platform ahead commercially and position Metabolix as a
leader in the cost effective production of a wide range of biobased
industrial chemicals."
Mr. Senechal brings to his new role more than 20 years of experience in
the chemicals industry in both consulting and engineering. Mr. Senechal
joined Metabolix in 2010 as director of strategy and commercial
development, focused on the strategic direction and commercialization
path for the Company's biobased industrial chemicals platform. From 2000
to 2010, Mr. Senechal served as a vice president for the chemicals,
petroleum and life sciences practices at Charles River Associates
International (CRA). At CRA, he focused on the development of business
strategies, operations improvement projects and due-diligence
engagements. From 1995 to 2000, Mr. Senechal was a senior manager at
Arthur D. Little, where he was responsible for a wide range of
consulting assignments for leading chemical companies across the globe.
Prior to his consulting career, Mr. Senechal was a project engineer
where he supervised the design, construction and start-up of industrial
facilities in several industries including commodity, specialty, fine
chemicals and pharmaceuticals. Mr. Senechal earned his MBA from the
University of Massachusetts, Boston, and his B.S. in mechanical
engineering from Laval University, Quebec, Canada.
About Metabolix
Metabolix, Inc. is an innovation-driven bioscience company delivering
sustainable solutions to the plastics, chemicals and energy industries.
Metabolix is developing and commercializing MirelTM and Mvera,TM
a family of high-performance bioplastics which are biobased and
biodegradable alternatives to many petroleum-based plastics. Metabolix's
biobased chemicals platform utilizes its novel "FAST" recovery process
to enable the production of cost-effective, "drop-in" replacements for
petroleum-based industrial chemicals. Metabolix is also developing a
platform for co-producing plastics, chemicals and energy from crops.
Metabolix has established an industry-leading intellectual property
portfolio that, together with its knowledge of advanced industrial
practice, provides a foundation for industry collaborations.
For more information, please visit www.metabolix.com.
(MBLX-G)
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements which are made
pursuant to the safe harbor provisions of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. The forward-looking statements in this release do
not constitute guarantees of future performance. Investors are cautioned
that statements in this press release which are not strictly historical
statements, including, without limitation, statements regarding the
ability to develop, commercialize and market biobased industrial
chemicals, constitute forward-looking statements. Such forward-looking
statements are subject to a number of risks and uncertainties that could
cause actual results to differ materially from those anticipated and are
detailed in Metabolix's filings with the Securities and Exchange
Commission, including its 10-K for the year ended December 31, 2011,
which was filed on March 12, 2012. Metabolix assumes no obligation to
update any forward-looking information contained in this press release
or with respect to the announcements described herein.
Media:
Metabolix
Lynne Brum, 617-682-4693
LBrum@metabolix.com
or
Schwartz
MSL Boston
Keith Giannini or Kirsten Swenson, 781-684-0770
metabolix@schwartzmsl.com
or
Investors:
ICR
James
Palczynski, 203-682-8229
james.palczynski@icrinc.com
Source: Metabolix, Inc.
News Provided by Acquire Media
